Omalizumab in Chronic Idiopathic Urticaria: Indian experience

Speciality: Dermatology

Description:

A warm welcome to all the medical professionals in this interesting session on Omalizumab in Chronic Idiopathic Urticaria: Indian experience.
Omalizumab, an anti-IgE monoclonal antibody, has shown significant success in the treatment of chronic idiopathic urticaria (CIU) in India, offering relief to patients who have not responded to standard antihistamine therapies. CIU, characterized by persistent hives and itching without a known cause, can severely impact quality of life. Omalizumab works by reducing IgE levels, thereby lowering the histamine release that causes the hives and swelling.
Indian clinical experience has demonstrated that omalizumab provides rapid and sustained symptom relief, with many patients experiencing a significant reduction in hives and itching within weeks of starting treatment. It is generally well-tolerated, and its once-monthly subcutaneous administration offers convenience for both patients and healthcare providers. As more patients in India have gained access to omalizumab, it has become a cornerstone in the management of difficult-to-treat CIU, improving both physical and emotional well-being for affected individuals.
Therefore, get an overall knowledge of Omalizumab in Chronic Idiopathic Urticaria: Indian experience. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars